Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599882 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL17734205 | 0.83 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL29445342 | 0.81 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL601568 | 0.81 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL17734265 | 0.81 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL17734210 | 0.81 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL17734206 | 0.80 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL597040 | 0.80 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL10122005 | 0.79 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL600983 | 0.79 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | UTI LIMITED PARTNERSHIP (CA) | 2019-03-12 | — | — | US | disclosed |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | CACNA1E, CACNA1G, TRPC6 | CNR2 80/4885CNR1 62/4885 |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | CACNA1E, CACNA1G, TRPC6 | CNR2 76/4885CNR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.